Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease).

Abstract

A 27-year-old woman with progressive diaphyseal dysplasia (Camurati-Engelmann disease) received pamidronate and corticosteroid therapy for bone pain. During therapy, disease activity was assessed serially using bone scintigraphy with Tc-99m HMDP. With pamidronate administration, the bone pain became worse and diaphyseal uptake of Tc-99m HMDP increased, whereas corticosteroid administration improved the bone pain and reduced the diaphyseal uptake. In this case, pamidronate and corticosteroid produced different effects. Bone scintigraphy allowed an objective assessment of the response to these treatments, accurately reflecting clinical symptoms.

• Authors: T Inaoka, N Shuke, J Sato, Y Ishikawa, K Takahashi, T Aburano, Y Makita
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 26 Issue 8 Pg. 680-2 (Aug 2001) ISSN: 0363-9762 [Print] United States
• PMID: 11452173 (Publication Type: Case Reports, Journal Article)

Chemical References

• Diphosphonates
• Prednisolone
• Pamidronate
• Technetium Tc 99m Medronate

Topics

• Administration, Oral
• Adult
• Camurati-Engelmann Syndrome (diagnostic imaging, drug therapy)
• Diphosphonates (administration & dosage)
• Drug Therapy, Combination
• Female
• Follow-Up Studies
• Humans
• Pain Measurement
• Pain, Intractable (diagnostic imaging, drug therapy)
• Pamidronate
• Prednisolone (administration & dosage)
• Radionuclide Imaging (methods)
• Sensitivity and Specificity
• Technetium Tc 99m Medronate